Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2023—KSL Diagnostics, Buffalo, NY, has opened a transplant immunology laboratory to serve the western New York region. KSL is the provider for Erie County Medical Center and Kaleida Health. ConnectLife, a community blood bank and federally designated not-for-profit organ procurement organization, uses KSL’s new lab and services Allegany, Cattaraugus, Chautauqua, Erie, Genesee, Niagara, Orleans, and Wyoming counties.
September 2023—Diagnostica Stago received an authorization to operate from the Department of Defense Health Agency (DHA) for the company’s Max Generation analyzers and middleware solution. The cybersecurity clearance allows Department of Defense military treatment facilities worldwide to connect Stago Max Generation systems to the DHA network.
September 2023—Siemens Healthineers announced that its Atellica CI analyzer for immunoassay and clinical chemistry testing has received FDA clearance and is available in many countries.
September 2023—Global Access Diagnostics announced the launch of IT-Leish, a UKCA-marked rapid test used for diagnosing visceral leishmaniasis. The company acquired the manufacturing rights for IT-Leish from Bio-Rad in September 2022 to prevent the test’s withdrawal from the market and support the World Health Organization’s strategic plan to eliminate life-threatening neglected tropical diseases.
September 2023—Thermo Fisher Scientific announced FDA clearance of its Brahms PlGF plus Kryptor and Brahms sFlt-1 Kryptor novel biomarkers for the risk assessment and clinical management of preeclampsia. The assays received FDA breakthrough designation in May.
September 2023—BD announced FDA 510(k) clearance for its BD Respiratory Viral Panel for the BD Max system. It is a single molecular diagnostic combination test that uses a single nasal or nasopharyngeal swab sample to determine if a patient has SARS-CoV-2, influenza A, influenza B, or respiratory syncytial virus. Results are available in about two hours.
September 2023—Verichem Laboratories offers a line of liquid-stable, multianalyte kits for the calibration verification of electrolyte assays for use with systems employing flame photometer, direct or indirect ion-selective electrode, or standard enzymatic/colorimetric testing methods. The Electrolyte Standard kit contains the analytes chloride, ionized calcium, lithium, potassium, and sodium and has a 21-month stability claim. The ISE Standard kit contains chloride, lithium, potassium, and sodium and has an 18-month stability claim. The Carbon Dioxide Standard kit and standalone CO2 Standard level F both have 15-month stability claims. All products are free of azides, glycols, surfactants, and other potentially interfering substances.
August 2023—Cole-Parmer introduced its North Sciences/Traceable TSi and TEC2 series ultra-low temperature freezers. The self-monitoring freezers are integrated with a Traceable data logger that is compatible with the TraceableLive cloud-based monitoring service, which provides audio and visual alerts via an Apple Watch, smartphone, tablet, or PC. The ULT freezers can reach temperatures down to −86°C and are ideal for the safe storage of samples and vaccines and compliant with Vaccines for Children storage requirements.
August 2023—A multilevel set of liquid-stable clinical reference materials for use with ammonia and iron testing are available from Verichem Laboratories. The five-level standard kit, along with an optional, standalone ultra-high sixth level, is designed for the calibration verification of ammonia and iron assays on a range of automated clinical systems, including from Abbott Diagnostics, Beckman Coulter, Roche Diagnostics, and Siemens Healthineers. The materials are treated as patient specimens and free of glycols, surfactants, azides, and other interfering substances. Iron concentration levels of 10–1,000 μg/dL are verified using standard reference materials from the National Institute of Standards and Technology, and ammonia concentrations of 10–2000 μg/dL are verified using reagent-grade standards from the American Chemical Society. Shelf life is 24 months.
August 2023—Illumina launched the latest version of its DRAGEN software, version 4.2, for analyzing next-generation sequencing data. New features of the software include increased single nucleotide variant and structural variation calling accuracy powered by an enhanced machine learning model and multigenome graph, improvements in small copy number variation calling accuracy with joint SV/CNV calling, and the addition of four targeted callers for carrier screening—HBA 1/2, CYP21A2, RHD/RHCE, and LPA.
